Companies › YolTech Therapeutics
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Genitourinary; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YOLT-203 Gene editing therapy for alanine-glyoxylate aminotransferase (AGXT) deficiency | AGXT | Phase 2 | Primary Hyperoxaluria Type 1 | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07587021 | YOLT-203 | Phase 2 | Primary Hyperoxaluria Type 1 | Genitourinary | Aug 2027 |
| NCT07776626 | YOLT-203 | Phase 1 | Primary Hyperoxaluria Type 1 | Genitourinary | Oct 2027 |
Cisen Pharmaceutical Levee Medical Vensica Therapeutics Urotronic Prokidney
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.